Close Menu

People in the News

Dec 09, 2020

Ares Genetics: Arne Materna, Andreas Posch, Achim Plum

OpGen subsidiary Ares Genetics has announced founding CEO and Managing Director Andreas Posch and Managing Director Achim Plum will step down from their positions, effective Dec. 31. They will both stay on as special advisors throughout 2021 to ensure a smooth transition.

Arne Materna has been appointed managing director and CEO, effective Jan. 1. Materna previously served as vice president, products at CosmosID and has held leadership roles at Qiagen, CLCbio, and Pacific Biosciences. He has particular expertise in microbiology and next-generation sequencing and has experience developing bioinformatics platforms and products.

Dec 03, 2020

Infinity Biologix: Amit Bhalla

Infinity Biologix  has appointed Amit Bhalla as its vice president and CFO. He will lead the company's financial operations as it enters its next phase of growth after spinning out from Rutgers University in August. IBX is a central lab that provides sample collection and processing, storage, analytical services, and scientific and technical support. It received Emergency Use Authorization from the US Food and Drug Administration for its saliva-based test for detecting SARS-CoV-2 in April.

Balla joins the firm after more than 20 years of experience on Wall Street and in the healthcare industry. He was most recently senior healthcare analyst at Lord, Abbett and previously had senior roles at Becton Dickinson, Citigroup, Morgan Stanley, and Johnson & Johnson.

Dec 01, 2020

Diadem: Tamas Bartfai

Alzheimer's disease test developer Diadem has named Tamas Bartfai, a neuroscientist and Alzheimer's disease researcher, as chair of its medical advisory board.

Bartfai is an international expert in the development of drugs targeting neurological diseases, including Alzheimer’s disease, the firm said.

In the past, he was a professor, chairman of molecular and integrative neurosciences, and director at the Dorris Neuroscience Center at the Scripps Research Institute, and an adjunct professor at Stockholm University, the University of Oxford, and the University of Pennsylvania.

Bartfai has served as a drug development senior executive or consultant to pharmaceutical companies, including AstraZeneca, Roche, Novartis, and Pfizer. He has also been a consultant to biotech venture capitalists and helped launch a number of biotech startups.

Nov 25, 2020

Interpace Biosciences: Thomas Burnell, Jack Stover

Interpace Biosciences said that current President and CEO Jack Stover will retire effective Dec. 31, 2020, and will be replaced as president and CEO by Thomas Burnell. Stover will also step down from the company's board of directors once Burnell joins the company and is appointed to the board, but will serve as an advisor to Interpace through the middle of 2021 to support the transition.

Burnell has previously served as president and CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories, and Eurofins Scientific. He has also previously held leadership roles with companies such as Elite One Source, Nebraska Heart Institute, and most recently the Pioneer Heart Institute.

Nov 25, 2020

Enzo Biochem: Ian Walters

Ian Walters has been appointed to the board of directors of Enzo Biochem. He is the CEO and director of Portage Biotech, a biopharmaceutical firm developing immuno-oncology treatments. Previously, he was executive director of global oncology clinical research and business development at Bristol-Myers Squibb and medical director at Millennium Pharmaceuticals. Walters holds an MBA from the Wharton School of the University of Pennsylvania and an MD from Albert Einstein College of Medicine.

Nov 23, 2020

Thermo Fisher Scientific: Alexandra Keith

Alexandra Keith has been elected to the board of directors of Thermo Fisher Scientific. She is the CEO of Procter & Gamble's global beauty business and a member of P&G's global leadership council. Over the past 30 years, she has served in a variety of roles at P&G, including in manufacturing, logistics, communications, and product innovation.

Nov 19, 2020

Icahn School of Medicine at Mount Sinai: Alison Goate

Alison Goate has been named chair of the department of genetics and genomics sciences at the Icahn School of Medicine at Mount Sinai, effective Jan. 1, 2021.

Goate is the Willard T.C. Johnson research professor of neurogenetics and a professor of genetics and genomic science, neuroscience, and neurology. Her research focuses on genetic risk factors of neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia.

She came to Mount Sinai in 2015 as founding director of the Ronald M. Loeb Center for Alzheimer's Disease and is a member of the National Academy of Medicine and a fellow of the American Association for the Advancement of Science. Goate holds a doctorate from the University of Oxford.

Nov 19, 2020

Specific Diagnostics: Jeff Holman

Specific Diagnostics this week said that it has named Jeff Holman VP of global marketing. Holman most recently served as head of sales for the Core Laboratory vertical for Roche Diagnostics. He will lead all marketing and branding activities related to Specific's Reveal System and market launch in Europe, and subsequent launch of the rapid antimicrobial susceptibility testing system in the US, the firm said.

Nov 19, 2020

Natera: Monica Bertagnolli

Monica Bertagnolli has been appointed to the board of directors of Natera. She is a professor of surgery at Harvard Medical School and associate surgeon in the division of surgical oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. In addition, she is the CEO of Alliance Foundation Trial, a nonprofit organization that conducts international cancer clinical trials, as well as VP of the Coalition of Cancer Cooperative Groups. Bertagnolli holds an undergraduate degree in engineering from Princeton University and a medical degree from the University of Utah College of Medicine.

Nov 18, 2020

Quanterix: William Geist

Quanterix has named William Geist as chief operating officer. Geist most recently served as vice president and general manager for two of Thermo Fisher Scientific's protein and cell analysis and qPCR business units. He also held a key leadership role in Thermo Fisher's COVID-19 task force in its biosciences division. Prior to this, Geist held numerous sales, marketing, and business development leadership roles including vice president of sales, marketing, and business development at Qiagen's Quanta BioSciences. He holds a BA in biology from Dartmouth College.

Nov 17, 2020

Day Zero Diagnostics: Dekel Gelbman, Robin Patel, Sally Hojvat

Day Zero Diagnostics has appointed Dekel Gelbman as senior VP of business development and strategy, Robin Patel as a member of its scientific advisory board, and Sally Hojvat as a regulatory strategy advisor.

Gelbman joins the company from FDNA, where he was the founding CEO. Before that, he was a corporate and transactional attorney in Israel and the US.

Patel is the director of the infectious diseases research laboratory and co-director of the clinical bacteriology laboratory at the Mayo Clinic.

Hojvat is a senior consultant at Partners in Diagnostics. Prior to that, she was the director of the division of microbiology devices at the Center for Devices and Radiological Health at the US Food and Drug Administration.

Nov 17, 2020

Veracyte: John Hanna, Morten Frost

Veracyte has appointed John Hanna as its general manager of endocrinology, breast cancer, and lymphoma; and Morten Frost as its general manager of pulmonology. The firm has established the general manager structure as part of its plans for global expansion.

Hanna currently serves as Veracyte's chief commercial officer. Prior to Veracyte, Frost most recently held the role of head of global marketing for pathology and companion diagnostics at Agilent Technologies.

Nov 17, 2020

Inivata: Alan Schafer

Inivata has appointed Alan Schafer as its chief technology officer. Schafer previously served as CEO of 14M Genomics, a cancer molecular diagnostic firm. Prior to 14M Genomics, he served as CEO of Population Genetics. He has also served as global VP of technology development at GlaxoSmithKline and VP of genetics at Incyte. 

Nov 13, 2020

Centogene: Jonathan Sheldon

Jonathan Sheldon has been nominated as a member of the supervisory board of Centogene. He will serve as an interim member with immediate effect until his confirmation at an upcoming shareholder meeting. Sheldon is senior VP of the digital insights business area at Qiagen and has led Qiagen's Digital Insights global business since 2018. Prior to this, he was global VP at Oracle Health Sciences.

Nov 11, 2020

Unilabs: Victoria Bell

Unilabs has appointed Victoria Bell its group chief financial officer ad interim, replacing Andrew Derodra who has left the Geneva-based diagnostics services provider for personal reasons. Bell has held senior roles in companies such as Centrient Pharmaceuticals, Wittur Group, JP Morgan, and Société Générale.                     

Nov 11, 2020

Magnolia Medical Technologies: Gary Doern

Blood sample collection device developer Magnolia Medical Technologies has appointed Gary Doern to its medical and scientific advisory board. He is professor emeritus of pathology at the University of Iowa Carver College of Medicine. His leadership roles include head of the American Board of Medical Microbiology, and chair of the clinical microbiology division of the American Society for Microbiology. Doern was also editor in chief of the Journal of Clinical Microbiology.

Nov 10, 2020

Spartan Bioscience: Roger Eacock, Others

Spartan Bioscience, a Canadian company specializing in portable molecular diagnostic testing, has announced several new executive and board appointments. Roger Eacock joins the company as its new CEO and board member. Eacock has previously held leadership roles with companies such as TerrAscend, Sobeys, SunOpta, and Dell.

Eacock's appointment follows the election of three new members to Spartan's board of directors. Board Chair Rochelle Stenzler is a pharmacist with extensive experience as a senior executive in healthcare, retailing, consumer packaged goods, and interactive voice response technology. She has previously served as president of Revlon Canada and president and general manager of Pharma Plus Drugmarts.

Board member Arun Menawat is CEO of Profound Medical, which is developing a real-time MRI-guided thermal ultrasound system for incision-free ablation of abnormal or cancerous tissue. He is also former president and CEO of Novadaq Technologies.

Board member Maryscott Greenwood is partner and managing director of Crestview Strategy US, a public affairs consultancy. She is also CEO of the Canadian American Business Council.

Additionally, Lennie Ryer joins Spartan as CFO with more than 20 years of experience as CFO of several biotechnology companies including SQI Diagnostics and ConjuChem; and Trevor Brown joins Spartan as chief commercial officer, having previously served as vice president of precision medicine for Seracare Lifesciences and director of global strategic marketing at Luminex Molecular Diagnostics.

Finally, Jennifer Ross-Carriere has joined Spartan as chief legal and administrative officer. Ross-Carriere most recently served as general counsel, corporate secretary, and vice president, people and culture at IFS (previously Mxi Technologies).

Nov 09, 2020

Aspira Women's Health: Elena Ratner, Kaile Zagger, Lesley Northrop, Gary Altwerger, Sandra Brooks

Aspira Women's Health made several appointments to it executive team, including Elena Ratner as global chief medical advisor, clinical and translational medicine. She is a gynecologic oncologist specializing in ovarian malignancies at the Smilow Cancer Hospital at Yale New Haven.

Additionally, Aspira, formerly called Vermillion, appointed Kaile Zagger its chief operating officer. She has more than 20 years of experience as an executive in healthcare, including at St. Jude Medical, Intuitive Surgical, and General Electric Healthcare.

Lesley Northrop was promoted Aspira's chief science officer. She was previously the company's global head of innovation and clinical development.

Also, Gary Altwerger was appointed global deputy chief medical advisor, clinical and translational medicine. He previously was assistant professor of obstetrics and gynecology, and Wellness committee director, Obstetrics, Gynecology and Reproductive Sciences at the Yale School of Medicine.

Aspira also appointed Sandra Brooks to its board of directors. The firm noted the board now has seven members with a female majority. Brooks is senior VP and CMO at Thomas Jefferson University Hospitals, Center City division, and a professor in the department of obstetrics and gynecology at Sidney Kimmel Medical College. She previously was a professor and director of the division of gynecology oncology at the University of Maryland.

Nov 05, 2020

Yourgene Health: Joanne Mason, Bill Chang

Joanne Mason has been promoted to CSO and director of Yourgene Health. Since joining the company in late 2019, she had been director of research and development. Previously, she was VP of biodiscovery at Cambridge Epigenetix and director of sequencing and sample acquisition at Genomics England. Mason holds a PhD in molecular and cellular biology from the University of Cambridge.

Bill Chang has taken on the role of chief entrepreneur at Yourgene Health while remaining a company director. In his new position, he will focus on new scientific collaborations and business ventures.

Nov 05, 2020

Micronoma: Eddie Adams, Greg Poore, Darryl Garrison

Micronoma has named Eddie Adams as chief scientific officer, company cofounder Greg Poore as chief analytic officer, and Darryl Garrison as chief operating officer.

Poore, now responsible for guiding further development of the firm's analytic and machine learning technology, is the first author of Micronoma's foundational Nature paper, a graduate of Duke University's biomedical engineering program, and currently a double-doctoral candidate in the University of California, San Diego's medical scientist training program.

Adams will lead the scientific development of Micronoma's diagnostic assays and its growing of the scientific team, with immediate responsibility for leading a utility trial for Micronoma's first offering, a diagnostic for the early detection of lung cancer. He holds a PhD from MIT and his background spans chemistry, immunology, nanotechnology, and molecular biology. He has developed diagnostics programs for the early detection of bloodstream infection and has extensive experience in sample preparation including commercializing methods and kits to extract nucleic acids for microbiome analyses.

Garrison holds more than 20 years of experience in the molecular diagnostic industry, having set up and run diagnostics laboratories at many of the major clinical cancer firms in Southern California. For Micronoma, he will establish the firm's CLIA labs, as well as assist with all processes and workflow implementation to ensure that the company is ready to process patient samples.

Nov 04, 2020

Genome Diagnostics: Seiamak Bahram

Genome Diagnostics has appointed Seiamak Bahram a scientific advisor to the company. He has extensive knowledge of the major histocompatibility complex, especially the MHC Class I chain-related molecules A and B and will advise Genome Diagnostics about relevant immunological targets and the use of diagnostic assays in hospital settings. Bahram is a professor and hospital practitioner in the faculty of medicine at the University of Strasbourg and department head of the central laboratory of immunology at the University Hospitals of Strasbourg, France.

Nov 02, 2020

Scope Fluidics: Carl Wittwer

Carl Wittwer has been appointed to the advisory committee of Scope Fluidics. Wittwer, who is credited as one of the creators of PCR, has specialized in developing ultra-rapid PCR chemistries and was a co-founder of BioFire Diagnostics. Wittwer will advise the Warsaw, Poland-based firm in the futher development of its 15-minute sample-to-answer multiplex PCR One system for which it is currently developing SARS-CoV-2 assays. 

Nov 02, 2020

Abingdon Health: Mary Tavener

Abingdon Health has appointed Mary Tavener as senior independent non-executive director, board member, and chair of its audit committee. 

Tavener served as chief financial officer and a board member of Advanced Medical Solutions for 19 years. At AMS, she was responsible for strategy and risk management, finance, operations, and regulatory and legal affairs. Tavener is a member of the Chartered Institute of Management Accountants and a fellow of the Association of Corporate Treasurers.

Oct 30, 2020

DotLab Scientific Advisory Board

DotLab, a women's health company developing a microRNA-based test for endometriosis, has formed its scientific advisory board. Appointees include Kristof Chwalisz, therapeutic area head urology, gynecology at Abbott Laboratories; Anula Jayasuriya, founder and managing director at EXXclaim Capital; Thomas Musci, former chief medical officer at Ariosa Diagnostics (acquired by Roche) and former faculty member at the University of California, San Francisco; Harold Sauer, chairman of the department of obstetrics and gynecology at Bridgeport Hospital, part of the Yale New Haven Health System; Eric Surrey, medical director at the Colorado Center for Reproductive Medicine; and Robert Taylor, professor of obstetrics and gynecology and assistant dean and director of the Md-PhD program at the University at Buffalo.

Oct 29, 2020

CareDx: Peter Maag, Reginald Seeto

CareDx announced that current Chairman and CEO Peter Maag will assume the role of executive chairman of the board, effective Nov. 1, and that current President and Chief Business Officer (CBO) Reginald Seeto will then assume the role of president and CEO. Seeto will also join the company's board.

Maag joined CareDx in 2012 as CEO and led the company through its IPO. Seeto joined CareDx in 2018 as president and CBO, leading the company's commercial, clinical, manufacturing, and R&D organizations.